AR070816A1 - Farmaco de combinacion para tratar trastornos vasculares - Google Patents
Farmaco de combinacion para tratar trastornos vascularesInfo
- Publication number
- AR070816A1 AR070816A1 ARP090100806A ARP090100806A AR070816A1 AR 070816 A1 AR070816 A1 AR 070816A1 AR P090100806 A ARP090100806 A AR P090100806A AR P090100806 A ARP090100806 A AR P090100806A AR 070816 A1 AR070816 A1 AR 070816A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- salt
- arterial disease
- carbostiryl
- pharmaco
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Una combinacion caracterizada porque comprende como componentes activos un derivado de carbostirilo de la formula general (1) donde A es un grupo alquileno inferior, R es un grupo cicloalquilo, el enlace entre las posiciones 3 y 4 del esqueleto del carbostirilo es un enlace simple o un enlace doble, o una sal del mismo; y carnitina o una sal de la misma. Reivindicacion 2: La combinacion de la reivindicacion 1 caracterizada porque el derivado de carbostirilo es 6-[4-(1-ciclohexil-1H-tetrazol-5-il)butoxi]-3,4- dihidrocarbostirilo o una sal del mismo. Reivindicacion 3: Un medicamento para tratar la enfermedad arterial periférica oclusiva, caracterizado porque comprende la combinacion de la reivindicacion 1 o 2. Reivindicacion 5: El medicamento de la reivindicacion 3 o 4 caracterizado porque la enfermedad arterial periférica oclusiva es una enfermedad arterial oclusiva aguda, tromboangeítis obliterante, arteriosclerosis obliterante, estenosis espinal lumbar, o claudicacion intermitente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008065448 | 2008-03-14 | ||
JP2008118289 | 2008-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070816A1 true AR070816A1 (es) | 2010-05-05 |
Family
ID=41065644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100806A AR070816A1 (es) | 2008-03-14 | 2009-03-06 | Farmaco de combinacion para tratar trastornos vasculares |
Country Status (14)
Country | Link |
---|---|
US (2) | US8980919B2 (es) |
EP (1) | EP2254578A2 (es) |
JP (2) | JP5574989B2 (es) |
KR (1) | KR101632448B1 (es) |
CN (2) | CN102026638B (es) |
AR (1) | AR070816A1 (es) |
AU (1) | AU2009224214B2 (es) |
BR (1) | BRPI0909291A8 (es) |
CA (1) | CA2717351A1 (es) |
CL (1) | CL2009000589A1 (es) |
PE (1) | PE20091675A1 (es) |
RU (1) | RU2506950C2 (es) |
TW (1) | TW200944204A (es) |
WO (1) | WO2009113741A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011158110A2 (en) | 2010-04-28 | 2011-12-22 | Nuformix Limited | Cilostazol cocrystals and compositions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968719A (en) * | 1989-04-03 | 1990-11-06 | Sigma Tau, Industrie Farmaceutiche Riunite Spa | Method for treating vascular disease |
AU1295700A (en) * | 1998-11-26 | 2000-06-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia |
IT1306722B1 (it) | 1999-10-08 | 2001-10-02 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di |
US6871689B2 (en) * | 2001-02-07 | 2005-03-29 | Disa Industries A/S | Sand moulding machine with improved sand blow |
US20060160896A1 (en) * | 2002-02-04 | 2006-07-20 | Jallal Messadek | Therapeutic treatment |
TWI323660B (en) * | 2003-02-25 | 2010-04-21 | Otsuka Pharma Co Ltd | Pten inhibitor or maxi-k channels opener |
EP2275106A1 (en) * | 2005-09-15 | 2011-01-19 | Otsuka Pharmaceutical Co., Ltd. | Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects |
-
2009
- 2009-03-06 AR ARP090100806A patent/AR070816A1/es unknown
- 2009-03-09 TW TW098107509A patent/TW200944204A/zh unknown
- 2009-03-12 CL CL2009000589A patent/CL2009000589A1/es unknown
- 2009-03-13 CN CN200980117788.1A patent/CN102026638B/zh not_active Expired - Fee Related
- 2009-03-13 CN CN201510300300.6A patent/CN104906097A/zh active Pending
- 2009-03-13 BR BRPI0909291A patent/BRPI0909291A8/pt not_active IP Right Cessation
- 2009-03-13 PE PE2009000377A patent/PE20091675A1/es not_active Application Discontinuation
- 2009-03-13 JP JP2010550400A patent/JP5574989B2/ja not_active Expired - Fee Related
- 2009-03-13 US US12/922,414 patent/US8980919B2/en not_active Expired - Fee Related
- 2009-03-13 RU RU2010141982/15A patent/RU2506950C2/ru not_active IP Right Cessation
- 2009-03-13 CA CA2717351A patent/CA2717351A1/en not_active Abandoned
- 2009-03-13 KR KR1020107022826A patent/KR101632448B1/ko active IP Right Grant
- 2009-03-13 AU AU2009224214A patent/AU2009224214B2/en not_active Ceased
- 2009-03-13 EP EP09719733A patent/EP2254578A2/en not_active Withdrawn
- 2009-03-13 WO PCT/JP2009/055554 patent/WO2009113741A2/en active Application Filing
-
2014
- 2014-04-23 JP JP2014089474A patent/JP5837128B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-06 US US14/616,569 patent/US20150150865A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200944204A (en) | 2009-11-01 |
AU2009224214B2 (en) | 2013-12-12 |
CA2717351A1 (en) | 2009-09-17 |
JP2011513480A (ja) | 2011-04-28 |
WO2009113741A3 (en) | 2010-04-29 |
CN102026638A (zh) | 2011-04-20 |
JP2014159458A (ja) | 2014-09-04 |
EP2254578A2 (en) | 2010-12-01 |
CN104906097A (zh) | 2015-09-16 |
US20110015224A1 (en) | 2011-01-20 |
KR101632448B1 (ko) | 2016-06-21 |
RU2506950C2 (ru) | 2014-02-20 |
CL2009000589A1 (es) | 2010-03-26 |
JP5574989B2 (ja) | 2014-08-20 |
RU2010141982A (ru) | 2012-04-20 |
BRPI0909291A2 (pt) | 2015-08-11 |
CN102026638B (zh) | 2015-06-24 |
JP5837128B2 (ja) | 2015-12-24 |
BRPI0909291A8 (pt) | 2016-07-12 |
US8980919B2 (en) | 2015-03-17 |
US20150150865A1 (en) | 2015-06-04 |
WO2009113741A2 (en) | 2009-09-17 |
KR20100123909A (ko) | 2010-11-25 |
AU2009224214A1 (en) | 2009-09-17 |
PE20091675A1 (es) | 2009-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066664A1 (es) | Un medicamento para tratar enfermedad de alzheimer | |
CU20120015A7 (es) | Piridina y pirazina como derivados de moduladores de la proteína kinasa | |
BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
CR20120289A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
CR20140537A (es) | Compuesto heterocíclico nitrogenado | |
AR065033A1 (es) | Metodos para prevenir y tratar trastornos neurodegenerativos | |
EA201001585A1 (ru) | Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк) | |
ATE530526T1 (de) | Lactam-substituierte dicarbonsäuren und ihre verwendung | |
DOP2012000174A (es) | Metodo de tratamiento | |
EA201792071A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
WO2015091414A3 (de) | Substituierte piperidinyl-tetrahydrochinoline und ihre verwendung als alpha-2c adrenorezeptor antagonisten | |
AR092247A1 (es) | INHIBIDORES DE LA b-SECRETASA | |
AR067446A1 (es) | Un medicamento para tratar higado graso que comprende cilostazol | |
CO6430497A2 (es) | Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento | |
BR112015022849A2 (pt) | sais de adição de base de nitroxolina e usos dos mesmos | |
AR070816A1 (es) | Farmaco de combinacion para tratar trastornos vasculares | |
DOP2010000156A (es) | Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca | |
AR067746A1 (es) | Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol | |
AR065855A1 (es) | Un medicamento para tratar la esquizofrenia que comprende cilostazol | |
AR065588A1 (es) | Un medicamento para tratar enfermedad pulmonar obstructiva cronica | |
UY32827A (es) | Inhibidores de catepsina c | |
EA201100826A1 (ru) | Холиновые соли янтарной кислоты для лечения депрессий, страхов, шизофрении, нарушений сна и эпилепсии | |
TH103574A (th) | การรักษาร่วมกันของสารภูมิต้านทานต้าน cd20 ชนิด ii กับสารยับยั้งโปรตีเอโซม | |
TH154733A (th) | อนุพันธ์เตตระไฮโดร-ไพริโด-ไพริมิดีน (tetrahydro-pyrido-pyrimidine) | |
TH172004A (th) | องค์ประกอบ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |